Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $11.00

Sana Biotechnology (NASDAQ:SANA) had its target price upped by HC Wainwright from $8.00 to $11.00 in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities analysts also recently issued reports on the stock. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.25.

Sana Biotechnology Stock Down 14.9 %

Sana Biotechnology stock opened at $3.66 on Wednesday. The firm has a fifty day simple moving average of $2.40 and a two-hundred day simple moving average of $4.06. Sana Biotechnology has a twelve month low of $1.52 and a twelve month high of $12.00. The company has a market capitalization of $817.16 million, a PE ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, equities analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology in the 3rd quarter worth $29,000. Stifel Financial Corp bought a new position in Sana Biotechnology during the third quarter valued at approximately $43,000. EP Wealth Advisors LLC purchased a new position in Sana Biotechnology during the 3rd quarter valued at approximately $45,000. Blue Trust Inc. increased its stake in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after acquiring an additional 12,154 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Sana Biotechnology during the 2nd quarter worth approximately $73,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.